352 related articles for article (PubMed ID: 28107410)
1. Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients.
Nattenmüller J; Wochner R; Muley T; Steins M; Hummler S; Teucher B; Wiskemann J; Kauczor HU; Wielpütz MO; Heussel CP
PLoS One; 2017; 12(1):e0169136. PubMed ID: 28107410
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
3. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
4. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
[TBL] [Abstract][Full Text] [Related]
5. Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer.
Okumura S; Kaido T; Hamaguchi Y; Kobayashi A; Shirai H; Yao S; Yagi S; Kamo N; Hatano E; Okajima H; Takaori K; Uemoto S
Ann Surg Oncol; 2017 Nov; 24(12):3732-3740. PubMed ID: 28871520
[TBL] [Abstract][Full Text] [Related]
6. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
Degens JHRJ; Sanders KJC; de Jong EEC; Groen HJM; Smit EF; Aerts JG; Schols AMWJ; Dingemans AC
Lung Cancer; 2019 Jul; 133():130-135. PubMed ID: 31200819
[TBL] [Abstract][Full Text] [Related]
8. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.
Fujiwara N; Nakagawa H; Kudo Y; Tateishi R; Taguri M; Watadani T; Nakagomi R; Kondo M; Nakatsuka T; Minami T; Sato M; Uchino K; Enooku K; Kondo Y; Asaoka Y; Tanaka Y; Ohtomo K; Shiina S; Koike K
J Hepatol; 2015 Jul; 63(1):131-40. PubMed ID: 25724366
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
Charette N; Vandeputte C; Ameye L; Bogaert CV; Krygier J; Guiot T; Deleporte A; Delaunoit T; Geboes K; Van Laethem JL; Peeters M; Demolin G; Holbrechts S; Flamen P; Paesmans M; Hendlisz A
BMC Cancer; 2019 Feb; 19(1):134. PubMed ID: 30744591
[TBL] [Abstract][Full Text] [Related]
12. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
[TBL] [Abstract][Full Text] [Related]
14. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer.
Kim EY; Lee HY; Kim YS; Park I; Ahn HK; Cho EK; Jeong YM; Kim JH
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 28426181
[TBL] [Abstract][Full Text] [Related]
16. Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer.
Miki M; Lee L; Hisano T; Sugimoto R; Furukawa M
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e297-e305. PubMed ID: 34818466
[TBL] [Abstract][Full Text] [Related]
17. High visceral fat attenuation and long-term mortality in a health check-up population.
Lee JH; Choi SH; Jung KJ; Goo JM; Yoon SH
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1495-1507. PubMed ID: 37016984
[TBL] [Abstract][Full Text] [Related]
18. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact.
Prado CM; Cushen SJ; Orsso CE; Ryan AM
Proc Nutr Soc; 2016 May; 75(2):188-98. PubMed ID: 26743210
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
